08:32 AM EDT, 10/17/2024 (MT Newswires) -- AbbVie ( ABBV ) said Thursday that the US Food and Drug Administration approved Vyalev as a subcutaneous 24-hour infusion of levodopa-based therapy to treat motor fluctuations in adults with advanced Parkinson's disease.

The approval was based on a phase 3 study, which showed that continuous subcutaneous infusion of Vyalev was more effective than oral immediate-release carbidopa/levodopa.

The company said access to Vyalev will vary based on insurance, with Medicare coverage anticipated in H2 2025.

Price: 190.12, Change: -0.34, Percent Change: -0.18